Gonioscopy-assisted transluminal trabeculotomy outcomes in patients with highly advanced glaucoma.

BACKGROUND/OBJECTIVES

No data regarding the outcomes of GATT in patients with highly advanced glaucoma are available. The aim of this study is to fill in this gap.

SUBJECTS/METHODS

This is a multicentre, retrospective, and case-control study including highly advanced glaucoma patients (HVF Mean Deviation, MD -20 dB). Sixty eyes (31 GATT stand-alone and 29 Phaco-GATT eyes) were included in each group. The SG and CG were compared until 12 months of follow-up, and survival analyses were performed.

RESULTS

The preoperative MD was -25.95 ± 3.64 dB in the SG and -7.96 ± 5.25 dB in the CG (p < 0.001). Preoperative IOP was 21.5 ± 8.2 mmHg in the SG on 3.4 ± 1.4 medications, and 20.8 ± 7.3 mmHg in the CG (p = 0.6) on 3.0 ± 0.9 medications (p = 0.1). At the 12-month visit, IOP was reduced by 39.1 ± 26.6% in the SG and 36.0 ± 18.7% in the CG (p = 0.4), and the number of preoperative medications was reduced by 62.2 ± 33.2% in the SG and 65.5 ± 37.4% in the CG (p = 0.6), with 93.3% of the eyes in the SG and 90.0% of the eyes in the CG having an IOP ≤ 14 mmHg, with or without medication (p = 0.5). No serious adverse events were observed in any of the groups.

CONCLUSION

GATT is a safe and effective surgical option for patients with highly advanced glaucoma.